![Little Sparrows Technologies, a neonatal medical device startup secures $3million in seed funding. The supporters were kept a secret. The money will be used by the business to increase operations and development initiatives.](https://startuprise.io/wp-content/uploads/2024/05/MA-based-Little-Sparrows-Technologies-Secures-3Million-in-Seed-Funding.webp)
Little Sparrows Technologies, a neonatal medical device startup secures $3million in seed funding. The supporters were kept a secret. The money will be used by the business to increase operations and development initiatives.
Little Sparrows Technologies is a medical device firm founded in 2013 by Harvard physicians Drs. Donna Brezinski, a neonatologist, and Gary Gilbert, a haematologist. The company’s mission is to discover novel solutions to improve babies’ well-being globally.
Read also – [Funding News] MA-based Multitude Insights Secures an Investment from NEC X
In hospital and home settings in the US and overseas, the company’s first commercially available equipment, bili-hutTM newborn phototherapy, provides quick and efficient treatment for jaundice in neonates. In 2019, it was granted FDA 510(k) approval.
Additionally, Douglas A. Treco, PhD, Georgia McGaughey, PhD, and Francis Kim were added to the board by the corporation.
Donna Brezinski said: āWe are extremely fortunate to have assembled a team of world-class board members with proven track records who can offer their deep industry knowledge and strategic insights as we work toward growing our customer base in the US and globally for the benefit of newborns worldwide.ā
About Little Sparrows Technologies
Little Sparrows Technologies is an award-winning medical device startup firm founded in 2013 by Harvard physicians Drs. Donna Brezinski, a neonatologist, and Gary Gilbert, a haematologist. The company’s mission is to develop creative solutions to improve the global well-being of infants.
With FDA 510(k) certification in 2019, the company’s first commercially available product, bili-hutTM newborn phototherapy, is a tried-and-true, game-changing breakthrough that makes it possible to treat neonatal jaundice quickly and effectively in both hospital and home settings in the US and overseas.